-
公开(公告)号：US08962808B2
公开(公告)日：2015-02-24
申请号：US13696291
申请日：2011-05-05
申请人： Edward L. Chan , James Keller
发明人： Edward L. Chan , James Keller
CPC分类号： C12Q1/6886 , C07K14/71 , C07K16/40 , C07K2319/00 , C07K2319/23 , C07K2319/42 , C07K2319/43 , C07K2319/60 , C12N9/12 , G01N33/57407 , G01N33/74 , G01N2333/71 , G01N2800/56
摘要： Described herein are truncated EGF receptor polypeptides, nucleic acids encoding them, and methods of using them to help select a method of treatment for an EGFR-related cancer, to predict clinical outcome, and to detect micrometastases or minimal residual disease. High EGFR expression and phosphorylated EGFR predicts poor survival in head and neck cancer patients, but does not correlate with advanced stage disease. In our studies, we determined that clinical biological correlates are likely to be more accurate when different aspects of EGFR are evaluated in combination. We analyzed EGFR phosphorylation, expression and mutations in 60 primary head and neck tumors. We not only found that head and neck tumors with either truncated or activated EGFR tend to have higher tumor and nodal stage, but also discovered three EGFR truncations.
摘要翻译： 本文描述的是截短的EGF受体多肽，编码它们的核酸，以及使用它们帮助选择EGFR相关癌症的治疗方法，预测临床结果以及检测微转移或微小残留疾病的方法。 高EGFR表达和磷酸化EGFR预测头颈癌患者的生存率差，但与晚期阶段疾病无关。 在我们的研究中，我们确定临床生物相关性可以更准确地评估EGFR的不同方面。 我们分析了60例原发性头颈部肿瘤中的EGFR磷酸化，表达和突变。 我们不仅发现具有截短或活化的EGFR的头颈部肿瘤倾向于具有较高的肿瘤和淋巴结阶段，而且还发现三个EGFR截短。
-
公开(公告)号：US20130210004A1
公开(公告)日：2013-08-15
申请号：US13696291
申请日：2011-05-05
申请人： Edward L. Chan , James Keller
发明人： Edward L. Chan , James Keller
CPC分类号： C12Q1/6886 , C07K14/71 , C07K16/40 , C07K2319/00 , C07K2319/23 , C07K2319/42 , C07K2319/43 , C07K2319/60 , C12N9/12 , G01N33/57407 , G01N33/74 , G01N2333/71 , G01N2800/56
摘要： Described herein are truncated EGF receptor polypeptides, nucleic acids encoding them, and methods of using them to help select a method of treatment for an EGFR-related cancer, to predict clinical outcome, and to detect micrometastases or minimal residual disease. High EGFR expression and phosphorylated EGFR predicts poor survival in head and neck cancer patients, but does not correlate with advanced stage disease. In our studies, we determined that clinical biological correlates are likely to be more accurate when different aspects of EGFR are evaluated in combination. We analyzed EGFR phosphorylation, expression and mutations in 60 primary head and neck tumors. We not only found that head and neck tumors with either truncated or activated EGFR tend to have higher tumor and nodal stage, but also discovered three EGFR truncations.
摘要翻译： 本文描述的是截短的EGF受体多肽，编码它们的核酸，以及使用它们帮助选择EGFR相关癌症的治疗方法，预测临床结果以及检测微转移或微小残留疾病的方法。 高EGFR表达和磷酸化EGFR预测头颈癌患者的生存率差，但与晚期阶段疾病无关。 在我们的研究中，我们确定临床生物相关性可以更准确地评估EGFR的不同方面。 我们分析了60例原发性头颈部肿瘤中的EGFR磷酸化，表达和突变。 我们不仅发现具有截短或活化的EGFR的头颈部肿瘤倾向于具有较高的肿瘤和淋巴结阶段，而且还发现三个EGFR截短。
-
搜索结果
2 条记录 (耗时 0.016 秒)
